Vir Bio (VIR) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

VIR Stock Forecast


Vir Bio stock forecast is as follows: an average price target of $26.60 (represents a 183.88% upside from VIR’s last price of $9.37) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

VIR Price Target


The average price target for Vir Bio (VIR) is $26.60 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $15.00. This represents a potential 183.88% upside from VIR's last price of $9.37.

VIR Analyst Ratings


Buy

According to 10 Wall Street analysts, Vir Bio's rating consensus is 'Buy'. The analyst rating breakdown for VIR stock is 0 'Strong Buy' (0.00%), 7 'Buy' (70.00%), 3 'Hold' (30.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Vir Bio Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 02, 2024Gena WangBarclays$28.00$9.73187.77%198.83%
Jun 05, 2024Michael UlzMorgan Stanley$15.00$12.6618.48%60.09%
May 21, 2024Gena WangBarclays$27.00$9.69178.64%188.15%
Feb 21, 2023Paul ChoiGoldman Sachs$28.38$25.7410.26%202.88%
May 06, 2022Joseph StringerNeedham$35.00$21.8760.04%273.53%
Row per page
Go to

The latest Vir Bio stock forecast, released on Aug 02, 2024 by Gena Wang from Barclays, set a price target of $28.00, which represents a 187.77% increase from the stock price at the time of the forecast ($9.73), and a 198.83% increase from VIR last price ($9.37).

Vir Bio Price Target by Period


1M3M12M
# Anlaysts--3
Avg Price Target--$23.33
Last Closing Price$9.37$9.37$9.37
Upside/Downside-100.00%-100.00%148.99%

In the current month, the average price target of Vir Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vir Bio's last price of $9.37. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 02, 2024NeedhamBuyBuyHold
Aug 02, 2024BarclaysOverweightOverweightHold
Jun 05, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jun 05, 2024H.C. WainwrightBuyBuyHold
May 21, 2024BarclaysOverweightOverweightHold
May 07, 2024NeedhamBuyBuyHold
Mar 15, 2024H.C. WainwrightUnderperformUnderperformHold
Mar 15, 2024J.P. MorganBuyBuyHold
Sep 08, 2023Bank of America Securities-NeutralDowngrade
Feb 23, 2023Goldman SachsBuyBuyHold
Row per page
Go to

Vir Bio's last stock rating was published by Needham on Aug 02, 2024. The company gave VIR a "Buy" rating, the same as its previous rate.

Vir Bio Financial Forecast


Vir Bio Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue--------$56.29M$2.64M$3.80M$46.71M$21.79M$371.43M$-42.69M$1.23B$812.75M$103.62M$177.07M$1.98M$76.37K$1.93M$66.99M$5.72M$980.00K$1.40M
Avg Forecast$13.60M$10.98M$14.61M$18.21M$8.14M$5.54M$7.53M$11.71M$11.18M$8.71M$22.39M$50.15M$149.61M$114.22M$200.72M$811.05M$622.96M$138.25M$84.56M$98.64M$4.81M$11.01M$3.90M$2.90M$2.57M$3.75M
High Forecast$26.75M$21.60M$28.75M$33.86M$21.67M$5.78M$7.53M$11.71M$34.10M$17.70M$44.04M$98.65M$294.32M$114.22M$200.72M$811.05M$622.96M$138.25M$84.56M$98.64M$4.81M$11.01M$3.90M$2.90M$2.57M$3.75M
Low Forecast$3.14M$2.53M$3.37M$2.57M$1.18M$5.31M$7.53M$11.71M$692.44K$4.25M$5.17M$11.58M$34.53M$114.22M$200.72M$811.05M$622.96M$138.25M$84.56M$98.64M$4.81M$11.01M$3.90M$2.90M$2.57M$3.75M
# Analysts11124222463344443333333344
Surprise %--------5.04%0.30%0.17%0.93%0.15%3.25%-0.21%1.52%1.30%0.75%2.09%0.02%0.02%0.18%17.20%1.97%0.38%0.37%

Vir Bio's average Quarter revenue forecast for Mar 24 based on 2 analysts is $11.71M, with a low forecast of $11.71M, and a high forecast of $11.71M. VIR's average Quarter revenue forecast represents a -79.19% decrease compared to the company's last Quarter revenue of $56.29M (Dec 23).

Vir Bio EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11124222463344443333333344
EBITDA--------$-114.87M$-186.73M$-215.19M$-130.27M$-159.38M$208.55M$-212.24M$1.11B$547.41M$112.25M$63.27M$-167.31M$1.34M$-83.16M$-29.75M$-75.92M$-62.46M$-47.12M
Avg Forecast$-5.83M$-4.71M$-6.26M$-7.80M$-3.49M$-2.37M$-3.22M$-527.51M$-4.79M$-3.73M$-9.59M$-564.18M$-64.11M$-48.94M$-86.01M$-603.40M$-266.94M$-59.24M$-36.24M$-645.35M$-2.06M$-4.72M$-1.67M$-50.13M$-1.10M$-35.82M
High Forecast$-1.35M$-1.09M$-1.45M$-1.10M$-506.29K$-2.27M$-3.22M$-422.01M$-296.71K$-1.82M$-2.21M$-451.34M$-14.80M$-48.94M$-86.01M$-482.72M$-266.94M$-59.24M$-36.24M$-516.28M$-2.06M$-4.72M$-1.67M$-40.11M$-1.10M$-28.65M
Low Forecast$-11.46M$-9.26M$-12.32M$-14.51M$-9.29M$-2.47M$-3.22M$-633.01M$-14.61M$-7.58M$-18.87M$-677.02M$-126.12M$-48.94M$-86.01M$-724.08M$-266.94M$-59.24M$-36.24M$-774.42M$-2.06M$-4.72M$-1.67M$-60.16M$-1.10M$-42.98M
Surprise %--------23.99%50.02%22.43%0.23%2.49%-4.26%2.47%-1.84%-2.05%-1.89%-1.75%0.26%-0.65%17.63%17.82%1.51%56.75%1.32%

4 analysts predict VIR's average Quarter EBITDA for Dec 22 to be $-64.11M, with a high of $-14.80M and a low of $-126.12M. This is -130.74% lower than Vir Bio's previous annual EBITDA (Sep 22) of $208.55M.

Vir Bio Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11124222463344443333333344
Net Income--------$-115.92M$-163.41M$-194.78M$-140.96M$-101.60M$175.31M$-76.49M$518.62M$525.25M$110.43M$61.81M$-168.91M$-298.67$-84.61M$-31.17M$-77.24M$-63.77M$-48.31M
Avg Forecast$-107.96M$-111.71M$-111.37M$-106.59M$-118.72M$-143.83M$-122.30M$-532.55M$-137.72M$-164.92M$-164.44M$-569.57M$348.95M$-69.20M$44.79M$-609.17M$357.78M$-6.47M$-65.00M$-651.51M$-95.81M$-81.40M$-83.92M$-51.01M$-90.94M$-36.72M
High Forecast$-7.08K$-7.33K$-7.30K$-90.29M$-98.01M$-9.43K$-8.02K$-426.04M$-118.39M$-119.94M$-10.78K$-455.66M$418.74M$-69.20M$44.79M$-487.33M$357.78M$-6.47M$-65.00M$-521.21M$-95.81M$-81.40M$-83.92M$-40.81M$-90.94M$-29.38M
Low Forecast$-243.70M$-252.18M$-251.41M$-122.89M$-142.19M$-324.67M$-276.08M$-639.06M$-154.63M$-203.09M$-371.20M$-683.48M$279.16M$-69.20M$44.79M$-731.00M$357.78M$-6.47M$-65.00M$-781.82M$-95.81M$-81.40M$-83.92M$-61.21M$-90.94M$-44.07M
Surprise %--------0.84%0.99%1.18%0.25%-0.29%-2.53%-1.71%-0.85%1.47%-17.06%-0.95%0.26%0.00%1.04%0.37%1.51%0.70%1.32%

Vir Bio's average Quarter net income forecast for Dec 22 is $348.95M, with a range of $279.16M to $418.74M. VIR's average Quarter net income forecast represents a 99.04% increase compared to the company's last Quarter net income of $175.31M (Sep 22).

Vir Bio SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11124222463344443333333344
SG&A--------$43.09M$41.08M$47.10M$46.78M$38.74M$43.17M$41.59M$38.26M$55.78M$50.50M$28.78M$25.74M$70.94K$18.86M$16.39M$12.65M$11.81M$9.22M
Avg Forecast$152.88M$123.43M$164.28M$204.74M$91.50M$62.28M$84.59M$131.66M$125.62M$97.93M$251.66M$563.73M$37.06M$1.28B$2.26B$92.83M$7.00B$1.55B$950.58M$1.11B$54.11M$123.72M$43.79M$32.60M$28.87M$42.20M
High Forecast$300.74M$242.82M$323.17M$380.63M$243.60M$64.92M$84.59M$131.66M$383.27M$198.92M$495.08M$1.11B$44.47M$1.28B$2.26B$111.39M$7.00B$1.55B$950.58M$1.11B$54.11M$123.72M$43.79M$32.60M$28.87M$42.20M
Low Forecast$35.29M$28.49M$37.92M$28.86M$13.28M$59.64M$84.59M$131.66M$7.78M$47.82M$58.09M$130.12M$29.64M$1.28B$2.26B$74.26M$7.00B$1.55B$950.58M$1.11B$54.11M$123.72M$43.79M$32.60M$28.87M$42.20M
Surprise %--------0.34%0.42%0.19%0.08%1.05%0.03%0.02%0.41%0.01%0.03%0.03%0.02%0.00%0.15%0.37%0.39%0.41%0.22%

Vir Bio's average Quarter SG&A projection for Mar 24 is $131.66M, based on 2 Wall Street analysts, with a range of $131.66M to $131.66M. The forecast indicates a 205.54% rise compared to VIR last annual SG&A of $43.09M (Dec 23).

Vir Bio EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts11124222463344443333333344
EPS--------$-0.00$-1.22$-1.45$-1.06$-0.76$1.32$-0.58$3.93$4.01$0.85$0.48$-1.32$-0.00$-0.67$-0.27$-0.71$-0.69$-0.44
Avg Forecast$-0.79$-0.82$-0.81$-0.78$-0.87$-1.05$-0.89$-1.05$-1.01$-1.21$-1.20$-0.87$-0.35$-0.51$0.33$3.78$2.63$-0.05$-0.48$-0.21$-0.70$-0.60$-0.62$-0.53$-0.67$-0.69
High Forecast$-0.00$-0.00$-0.00$-0.66$-0.72$-0.00$-0.00$-0.00$-0.87$-0.88$-0.00$-0.00$-0.00$-0.51$0.33$3.78$2.63$-0.05$-0.48$-0.21$-0.70$-0.60$-0.62$-0.53$-0.67$-0.69
Low Forecast$-1.78$-1.85$-1.84$-0.90$-1.04$-2.38$-2.02$-2.37$-1.13$-1.49$-2.72$-1.97$-0.78$-0.51$0.33$3.78$2.63$-0.05$-0.48$-0.21$-0.70$-0.60$-0.62$-0.53$-0.67$-0.69
Surprise %--------0.00%1.01%1.20%1.21%2.19%-2.60%-1.76%1.04%1.53%-17.89%-1.01%6.20%0.00%1.12%0.44%1.35%1.03%0.64%

According to 4 Wall Street analysts, Vir Bio's projected average Quarter EPS for Dec 22 is $-0.35, with a low estimate of $-0.78 and a high estimate of $-0.00. This represents a -126.33% decrease compared to VIR previous annual EPS of $1.32 (Sep 22).

Vir Bio Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CVACCureVac$2.71$29.00970.11%Buy
VIRVir Bio$9.37$26.60183.88%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
VKTXViking Therapeutics$63.14$100.5059.17%Buy
AKROAkero Therapeutics$32.05$46.0043.53%Buy
BPMCBlueprint Medicines$91.88$109.7119.41%Buy
PTCTPTC Therapeutics$40.39$46.5015.13%Hold
KRYSKrystal Biotech$170.85$191.0011.79%Buy
MDGLMadrigal Pharmaceuticals$331.32$315.75-4.70%Buy
AMLXAmylyx Pharmaceuticals$5.70$5.33-6.49%Buy
KRTXKaruna Therapeutics$329.83$257.50-21.93%Buy

VIR Forecast FAQ


Yes, according to 10 Wall Street analysts, Vir Bio (VIR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 70.00% of VIR's total ratings.

Vir Bio (VIR) average price target is $26.6 with a range of $15 to $35, implying a 183.88% from its last price of $9.37. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for VIR stock, the company can go up by 183.88% (from the last price of $9.37 to the average price target of $26.6), up by 273.53% based on the highest stock price target, and up by 60.09% based on the lowest stock price target.

VIR's average twelve months analyst stock price target of $26.6 supports the claim that Vir Bio can reach $14 in the near future.

Vir Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $32.92M (high $46.68M, low $25.72M), average EBITDA is $-537M (high $-428M, low $-648M), average net income is $-917M (high $-524M, low $-1.382B), average SG&A $370.03M (high $524.77M, low $289.17M), and average EPS is $-3.868 (high $-0.717, low $-7.81). VIR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $57.41M (high $110.97M, low $11.61M), average EBITDA is $-24.6M (high $-4.977M, low $-47.549M), average net income is $-438M (high $-90.31M, low $-870M), average SG&A $645.33M (high $1.25B, low $130.55M), and average EPS is $-3.202 (high $-0.661, low $-6.368).

Based on Vir Bio's last annual report (Dec 2023), the company's revenue was $86.18M, which missed the average analysts forecast of $92.42M by -6.76%. Apple's EBITDA was $-684M, beating the average prediction of $-582M by 17.52%. The company's net income was $-615M, missing the average estimation of $-1.037B by -40.67%. Apple's SG&A was $178.05M, missing the average forecast of $1.04B by -82.86%. Lastly, the company's EPS was $-0.0046, missing the average prediction of $-4.293 by -99.89%. In terms of the last quarterly report (Dec 2023), Vir Bio's revenue was $56.29M, beating the average analysts' forecast of $11.18M by 403.68%. The company's EBITDA was $-115M, beating the average prediction of $-4.789M by 2298.68%. Vir Bio's net income was $-116M, missing the average estimation of $-138M by -15.83%. The company's SG&A was $43.09M, missing the average forecast of $125.62M by -65.70%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.008 by -99.91%